Goldman Sachs Group Inc Mi Nk Therapeutics, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $596 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|---|---|---|---|---|
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
Others Institutions Holding INKT
# of Institutions
21Shares Held
426KCall Options Held
0Put Options Held
0-
Jim Simons Renaissance Technologies LLC | New York, Ny102KShares$752,6310.0% of portfolio
-
Geode Capital Management, LLC Boston, MA96.1KShares$711,2360.0% of portfolio
-
Black Rock Inc. New York, NY87.2KShares$645,2500.0% of portfolio
-
High Tower Advisors, LLC Chicago, IL50.7KShares$375,0020.0% of portfolio
-
State Street Corp Boston, MA25.5KShares$188,8110.0% of portfolio
About MiNK Therapeutics, Inc.
- Ticker INKT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,775,100
- Market Cap $250M
- Description
- MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy...